Market-View-Feature-Image

View on market: Volatility persists, eagerly searching for growth

During Asian trading hours on Friday, US and European index futures moved higher, with optimism spilling over into parts of the Asian market. Technology stocks boosted Japanese shares, helping the regional benchmark advance, though some markets like South Korea and Australia slipped. In the US, stock indexes had a mixed finish. Early gains faded after a weak auction for long-term government bonds pushed Treasury yields higher. The Nasdaq managed to edge up, while the S&P 500 stayed almost unchanged and the Dow retreated. Indian markets staged a late recovery after a sharp intraday drop triggered by the US decision to double import tariffs on goods from India. A strong push from buyers in the final hour helped the Nifty close slightly higher, though the Sensex ended marginally lower. Overall, sentiment in global markets was cautious but supported by strength in select sectors, with investors weighing trade tensions against pockets of optimism in technology shares.

Key Quarterly Results for Today:

ABINFRA, ACE, AFCONS, BANCOINDIA, CHOLAHLDNG, CONCORD, DCMFINSERV, EQUITASBNK, EXCELINDUS, FRONTCAP, GENUSPOWER, HINDCOMPOS, HITECH, HITECHCORP, JKTYRE, KROSS, LAMBODHARA, LEMONTREE, MAHASTEEL, MANAPPURAM, MAXESTATES, MORGAN, NAUKRI, NCLIND, PGEL, POWERMECH, SBIN, SIEMENS, VOLTAS, ZENLABS.

Economic Calendar:

  • USD: Fed’s Balance Sheet Data on 08th August 2025.
  • IND: Foreign Reserves (USD) on 08th August 2025.
  • USD: Crore CPI (YoY) (MoM) (July) on 12th August 2025.
  • IND: Bank Loan and Deposit Growth Rate on 08th August 2025.

IPO Watch:

Company Open Close Price (Rs/-) View
JSW Cement Ltd. 07th Aug 11th Aug 139-147 Avoid
Regaal Resources Ltd. 12th Aug 14th Aug 96-102 Under Review

Brokerage Radar:

JEFFERIES ON HPCL:

Maintain Underperform; Hike TP to Rs 360 from Rs 315, Q1 Review: Operational miss; outlook weakening, Refining profitability outlook has weakened with challenge in sourcing Russian crude, Govt didn’t compensate LPG losses in Q1 as well.

JEFFERIES ON MAX FINANCIAL:

Maintain Buy with TP of Rs 1830, Q1: VNB Beat Led by Better Product Mix, Higher margins were driven by better product mix with stronger growth in retail protection, riders & Non-Par savings.

MORGAN STANLEY ON AU SFB:

Maintain Overweight with TP of Rs 860, RBI grants in-principle approval for Universal Banking License – A Big Positive, Allow AU Bank to improve its brand visibility, further boost liability franchise, and help sustain strong growth, License allows AU Bank to expand its product suite, customer base, and geographic reach.

CITI ON TITAN:

Maintain Buy; Hike TP to Rs 3900 from Rs 3800, 1QFY26: In-Line Growth and Profitability, Remain cautious on medium-term margins/profitability amid elevated competitive intensity, higher gold prices and adverse product mix, Aggressive store expansion by existing and new players implies need to invest in branding/marketing and higher discounting.

International Markets:

U.S & Europe:

Particulars     07th  Aug   Chg. Chg.(%)
Nasdaq 21,242.70 73.27 0.35
Dow 43,968.64 -224.48 -0.51
FTSE 9,100.77 -63.54 -0.70
CAC 7,709.32 74.29 0.96
DAX 24,192.50 268.14 1.11
Dow Fut.* 44,118.46 149.82 0.34

*As per 08th August.

Asian markets:

Particulars   08th  Aug Chg. Chg.(%)
GIFT Nifty                  24,641.00 -32.40 -0.13
Nikkei 41,934.00 874.85 2.13
Straits Times 4,241.70 -16.45 -0.39
Hang Seng 24,880.00 -201.63 -0.80
Shanghai                         3,639.87 0.20 0.01

Stocks strong on Chart:

Index F&O Cash
HDFC BANK HDFCAMC RALLIS INDIA
SBIN MOTHERSON CEAT
JIOFIN INOXWIND BEML
WIPRO ASHOKLEY MAX ESTATE
INFY PFC NIPPON AMC
ICICI BANK RECLTD MINDACORP

Commodities & Currency:

Particulars Current Price Chg.(%)
USD/INR 87.468 0.06
Brent 66.41 -0.03
Gold 101,670 0.40
Silver 115,205 1.36

FIIs & DIIs:

Particulars       07th Aug        06th Aug
FIIs                          -4,997.19 -4,999.10
DIIs 10,864.04 6,794.28

News Updates:

Zydus Lifesciences: Has received NOC from Health Canada for ZDS-Varenicline tablets 0.5 &1 mg. This is the group’s first NOC approval in Canada. Varenicline is used as an aid in smoking cessation.
NIBE: Has secured new orders worth Rs 29.22 crore from a domestic infrastructure and defence company for the supply of constructional details trackway and Breech Casings.
Oil India: Has signed a Memorandum of Understanding with IREL in Mumbai to cooperate and collaborate for development of Critical Minerals.
Biocon: Has approved a plan to acquire a 26% stake in Pro-zeal Green Power Sixteen and enter into a Power Purchase Agreement with them to buy solar power from a captive off-site solar energy plant.
Source: Moneycontrol, Bloomberg Quint, Investing

Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 214 

Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.

For analyst certification and other important disclosures, see the Disclosure Appendix, or go to www.elitewealth.in. Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India. (SEBI Registration No.: INH100002300)

Disclosure Appendix

Analyst Certification (For Reports)

Vindhyachal Prasad, Elite Wealth Limited, vindhyachal@elitestock.com

The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.

As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:

  • all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and
  • No part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.

Research Excerpts

This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit www.elitewealth.in.

Company-Specific Disclosures

Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting https://www.elitewealth.in, or emailing research@elitestock.com with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail research@elitestock.com.

Options related research:

If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at https://www.elitewealth.in

Other Disclosures

All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.

Ownership and material conflicts of interest Disclosure

Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, board member or employee of any company in the analyst’s area of coverage.

Country Specific Disclosures

India – For private circulation only, not for sale. Legal Entities Disclosures

Mr. Ravinder Parkash Seth is the Managing Director of Elite Wealth  Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone: 011-43035555, Facsimile: 011-22795783 and Website: www.elitewealth.in

EWL discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:

  1. Reports
  2. a) EWL or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;
  • EWL or its associates or relatives, have no actual/beneficial ownership of one %. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;
  • EWL or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;
    1. Compensation
    • EWL or its associates have not received any compensation from the subject company in the past twelve months;
    • EWL or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;
  • EWL or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
  • EWL or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
  • EWL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research
  1. In respect of Public Appearances
  • EWL or its associates have not received any compensation from the subject company in the past twelve months;
  • The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWL